MX2024009519A - Composiciones y metodos para el tratamiento mejorado de la enfermedad de pompe. - Google Patents

Composiciones y metodos para el tratamiento mejorado de la enfermedad de pompe.

Info

Publication number
MX2024009519A
MX2024009519A MX2024009519A MX2024009519A MX2024009519A MX 2024009519 A MX2024009519 A MX 2024009519A MX 2024009519 A MX2024009519 A MX 2024009519A MX 2024009519 A MX2024009519 A MX 2024009519A MX 2024009519 A MX2024009519 A MX 2024009519A
Authority
MX
Mexico
Prior art keywords
pompe disease
methods
compositions
improved treatment
provides methods
Prior art date
Application number
MX2024009519A
Other languages
English (en)
Spanish (es)
Inventor
Tahseen Mozaffar
Angela Smith
Original Assignee
Astellas Gene Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Gene Therapies Inc filed Critical Astellas Gene Therapies Inc
Publication of MX2024009519A publication Critical patent/MX2024009519A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
MX2024009519A 2022-02-03 2023-02-03 Composiciones y metodos para el tratamiento mejorado de la enfermedad de pompe. MX2024009519A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306361P 2022-02-03 2022-02-03
US202263402850P 2022-08-31 2022-08-31
PCT/US2023/061951 WO2023150688A2 (en) 2022-02-03 2023-02-03 Compositions and methods for improved treatment of pompe disease

Publications (1)

Publication Number Publication Date
MX2024009519A true MX2024009519A (es) 2024-08-14

Family

ID=87552969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009519A MX2024009519A (es) 2022-02-03 2023-02-03 Composiciones y metodos para el tratamiento mejorado de la enfermedad de pompe.

Country Status (11)

Country Link
US (1) US20250135038A1 (cg-RX-API-DMAC7.html)
EP (1) EP4472658A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505575A (cg-RX-API-DMAC7.html)
KR (1) KR20240145491A (cg-RX-API-DMAC7.html)
AU (1) AU2023216268A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250992A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002307A1 (cg-RX-API-DMAC7.html)
IL (1) IL314586A (cg-RX-API-DMAC7.html)
MX (1) MX2024009519A (cg-RX-API-DMAC7.html)
TW (1) TW202342092A (cg-RX-API-DMAC7.html)
WO (1) WO2023150688A2 (cg-RX-API-DMAC7.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658916B2 (en) * 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
AU2020372429A1 (en) * 2019-10-25 2022-04-28 Audentes Therapeutics, Inc. Compositions and methods for treating glycogen storage disorders
WO2021102107A1 (en) * 2019-11-19 2021-05-27 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders
US20230149428A1 (en) * 2020-02-14 2023-05-18 Asklepios Biopharmaceutical, Inc. Method of treating gene therapy associated toxicity with antibiotics
WO2021202599A2 (en) * 2020-04-01 2021-10-07 Valiant Biosciences, Llc Adeno-associated virus based compositions and related methods for inducing humoral immunity

Also Published As

Publication number Publication date
US20250135038A1 (en) 2025-05-01
WO2023150688A8 (en) 2023-11-16
WO2023150688A2 (en) 2023-08-10
WO2023150688A3 (en) 2023-09-28
EP4472658A4 (en) 2026-01-14
EP4472658A2 (en) 2024-12-11
AU2023216268A1 (en) 2024-08-15
IL314586A (en) 2024-09-01
CA3250992A1 (en) 2023-08-10
KR20240145491A (ko) 2024-10-07
CL2024002307A1 (es) 2024-12-27
JP2025505575A (ja) 2025-02-28
TW202342092A (zh) 2023-11-01

Similar Documents

Publication Publication Date Title
CL2020002945A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t
WO2020172343A3 (en) Treatment of liver injury
CL2020000384A1 (es) Métodos para tratar y/o prevenir la enfermedad de injerto contra huésped y/o hemorragia alveolar difusa y/o enfermedad veno-oclusiva asociada con trasplante de células madre hematopoyéticas.
MX2020006054A (es) Uso de un agonista del rxr en el tratamiento de canceres her2+.
Tan et al. Influence of neck dissection and preoperative irradiation on microvascular head and neck reconstruction—analysis of 853 cases
WO2019197605A3 (en) Drug combinations for use in the treatment of ras-mutant cancer
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2022006366A (es) Terapia de combinacion que implica compuestos de diarilo macrociclico.
MX2021005646A (es) Métodos de tratamiento de cáncer con agentes de unión a tubulina.
UY38948A (es) Régimen de dosificación para agentes anti-dll3
MX2024004213A (es) Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.
MX2023005234A (es) Terapia de combinacion de agente anti-cd19 y agente de direccionamiento a celulas b para el tratamiento de neoplasias malignas de celulas b.
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
MX2023013855A (es) Tratamiento del dolor asociado a la neuropatia periferica inducida por la quimioterapia.
MX2020013535A (es) Tratamiento de cáncer pulmonar de células no pequeñas (nsclc) en etapa iii y mitigación de las condiciones patológicas asociadas con el tratamiento.
MX2021013351A (es) Terapias de combinacion.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
WO2023150688A8 (en) Compositions and methods for improved treatment of pompe disease
WO2021011844A3 (en) Combination cancer therapy agents and methods
PH12023553216A1 (en) Compositions and methods for improved treatment of x-linked myotubular myopathy
MX2023001881A (es) Tratamiento con ribitol.
MX2022014586A (es) Métodos y composiciones para tratar la fuga vascular.
Mastorino et al. IL‐17 and IL‐23 inhibitors dose spacing in adult psoriatic patients: a real‐world pilot study
EA202191273A1 (ru) Применение тивозаниба для лечения субъектов с рефрактерным раком
MX2021015034A (es) Composiciones de lactobacillus y usos de las mismas.